Repligen Corp (RGEN)

Industry Medical Instruments & Supplies

This stock can be held in an Investment ISA and an Investment Account

Sell

$134.00

Buy

$180.00

arrow-down$-4.27 (-2.64%)

Prices updated at 12 Dec 2025, 22:59 EST

Prices minimum 15 mins delay

Prices in USD

Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. The company offers its products to life science companies, global biopharmaceutical companies, and contract manufacturers worldwide.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Medical Instruments & Supplies

Chairman

Mr. Tony J. Hunt

CEO

Mr. Olivier Loeillot

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

1,778

Head office

41 Seyon Street

Waltham

United States

02453

+1 781 250-0111

investors@repligen.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Jason K. Garland Chief Financial Officer	0.55m
Ms. Violetta A. Hughes Chief Accounting Officer	-
Mr. Glenn P. Muir Independent Director	0.10m
Ms. Karen A. Dawes, M.A. Lead Independent Director	0.16m
Mr. Nicolas M. Barthelemy Independent Director	0.09m
Dr. Martin D. Madaus,PhD Independent Director	0.08m
Mr. Tony J. Hunt Executive Chairman of the Board	0.73m
Ms. Carrie Eglinton Manner Independent Director	0.07m
Mr. Ralf Kuriyel, PhD Senior Vice President, Research and Development	0.40m
Dr. Rohin Mhatre, PhD Independent Director	0.07m
Dr. Konstantin Konstantinov, PhD Independent Director	0.07m
Mr. James R. Bylund Chief Operating Officer	0.47m
Mr. Olivier Loeillot Director, President and Chief Executive Officer	0.65m
Ms. Margaret A. Pax Independent Director	0.05m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
T Rowe Price Associates, Inc	6,392,245
BlackRock Inc	6,139,730
Vanguard Group Inc	5,077,172
T. Rowe Price Associates, Inc.	3,507,378
BlackRock Fund Advisors	3,157,679

Director dealings

Date chevron-l-regular chevron-r-regular	Action
05 Dec 2024	-
05 Dec 2024	-
21 Nov 2024	-
21 Nov 2024	-
21 Nov 2024	-
20 Nov 2024	-
20 Nov 2024	-
19 Nov 2024	-
19 Nov 2024	-
10 Sep 2024	-
10 Sep 2024	-
10 Sep 2024	-
10 Sep 2024	-
10 Sep 2024	-
10 Sep 2024	-
03 Sep 2024	-
03 Sep 2024	-
03 Sep 2024	-
03 Sep 2024	-
02 Aug 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.